Analysts are intrested in these 5 stocks: ( (AFRM) ), ( (GRAB) ), ( (VKTX) ), ( (PFE) ) and ( (LLY) ). Here is a breakdown of their recent ratings and the rationale behind them.
Affirm Holdings is catching the attention of analysts with its strong position in the Buy Now, Pay Later (BNPL) sector. Analyst Moshe Orenbuch has initiated coverage with a Buy rating and a target price of $50, citing Affirm’s superior underwriting capabilities and strategic partnerships with major e-commerce players like Amazon and Shopify. This positions Affirm to capture a significant share of the market, even as the economy faces uncertainties. Analyst Adam Frisch also rates Affirm as Outperform, highlighting its robust risk management and potential to benefit from a shift away from traditional credit. Both analysts agree that Affirm’s strategic moves and market positioning make it a promising investment.
Grab Holdings is making waves as a leading super app in Southeast Asia, with analyst Helena Wang initiating coverage with a Buy rating and a target price of $5.80. Grab’s extensive ecosystem, which includes ride-hailing, food delivery, and financial services, is well-positioned to capitalize on increasing urbanization and digital adoption. The company’s financial services segment is expanding rapidly, with a significant increase in its loan portfolio and a focus on profitability. Grab’s strong cash position and strategic investments in technology and electric vehicles signal long-term growth potential, making it an attractive option for investors.
Viking Therapeutics faces a challenging landscape in the obesity market, with analyst Richard Law giving it a Neutral rating and a price target of $30. Viking’s lead asset, VK2735, shows promise as a potent and safe treatment, but the competitive market and high barriers to entry pose significant challenges. The lack of clinical evidence for additional health benefits and the presence of more resourceful competitors make it difficult for Viking to gain a foothold. Despite these hurdles, there may be opportunities in the cash payment market, but investors should be cautious given the competitive pressures.
Pfizer is navigating a period of uncertainty, with analyst Asad Haider assigning a Hold rating and a target price of $25. The company faces challenges from declining COVID-related revenues and a lack of new product introductions. While Pfizer has undertaken strategic realignments, the benefits of these efforts are expected to take time to materialize. The company’s focus on mergers and acquisitions as a growth strategy could offset anticipated revenue shortfalls, but market volatility and policy uncertainties may impact the timing and success of such deals.
Eli Lilly & Co. is seen as a compelling investment opportunity, with analyst Asad Haider upgrading it to a Buy rating and setting a target price of $888. Eli Lilly’s leadership in the anti-obesity medication market, coupled with its strong manufacturing capabilities and strategic focus on large markets, positions it for significant growth. The company’s innovative approach and efficient product development processes are expected to drive upside from new product cycles. With a robust pipeline and a strategic focus on emerging markets, Eli Lilly is poised for long-term success, making it an attractive choice for investors.